-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: biopharma
Protect Yourself from a Hack Attack
Gone are the days when biotech’s biggest activist threats came from lab break-ins and physical attacks. Today almost anyone wishing to damage companies can steal, disrupt or harm employees 24-hours a day and from anywhere in the world. Hackers are anything BUT anonymous Last year the notorious group Anonymous took credit for hacking Monsanto Co. due to the company’s alleged “crimes against humanity.” It was the third hack Anonymous aimed against the the company, and Read More >
Landing the Big One: How to Score a Partnering Meeting with Big Biopharma
You’ve registered for the BIO Business Forum and received your log-in credentials. You’ve updated your drug assets and published your company’s profile. You peruse the list of other participating companies, looking for potential partners to message. Then, you see them. The big fish in the biopharma partnering pond. You decide to send them a meeting request and wonder, “How can I increase my chances of actually meeting with them face-to-face in Chicago?” To answer this Read More >
It Takes a Village: The New Pharma-VC Model for Biotech Investing
High-profile funding collaborations between pharmaceutical companies and traditional venture capital funds have made headlines in recent months, pooling resources and expertise in an attempt to source and develop the most successful drugs. BIO Executive Vice President Alan Eisenberg moderated It Takes a Village: The New Pharma-VC Model for Biotech Investing, a panel discussion about these new funding models, during the opening plenary session at the 2012 BIO Investor Forum. In the past, venture capital could Read More >
What Will It Take for the U.S. to Maintain Leadership in the Biopharma Industry?
The biopharmaceutical industry is an important contributor to U.S. economic growth and sustainability, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic output that totals more than $900 billion.[i] This significant economic impact is due to the high value-added nature of the sector, its extensive supply chain relationships, and high-wage jobs. As a result, gains and losses in the biopharmaceutical sector cascade across many important economic sectors Read More >
#BIF2012 Company Snapshot: Profil Institute for Translational Medicine
For the next Company Snapshot for the BIO Investor Forum, we’ve spoken with one of the presenting companies at the event, Profil Institute for Translational Medicine, Inc. To find out more about this organization and what they’re doing for biotech, please read below! You’ll be able to see their presentation onsite, Wednesday 10/10 at 9:30am in the Presidio Room. Company Snapshot What is your company’s lead product or technology? Based on collaborations with biopharma, Read More >
